Incyte Corporation INCY NASDAQ

Incyte Corporation (INCY) reported total assets of $6.96B and total liabilities of $1.8B for fiscal year 2025, resulting in total equity of $5.17B.

The company held $3.58B in cash and short-term investments. Total debt stood at $69.43M, with net debt of $-3.03B. The Debt-to-Equity (D/E) ratio was 0.01 (conservative).

Current ratio is 3.32, indicating strong short-term liquidity. Interest coverage is 553x (strong).

Criteria supported by this page:

• HEALTH (100/100, Pass) — Debt-to-Equity of 0.01, current ratio of 3.32, interest coverage 553x — balance sheet is strong
• MOAT (71/100) — Total assets $6.96B and equity $5.17B support the company's competitive scale
• VALUE (77/100) — Debt-to-Equity 0.01 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 82/100 with 6/7 criteria passed.

ARGX

argenx SE

$828.35

+2.36%

ALNY

Alnylam Pharmaceuticals, Inc.

$339.41

+1.92%

UTHR

United Therapeutics Corporation

$578.54

+0.16%

BGNE

BeiGene, Ltd.

$184.71

+0.49%

IONS

Ionis Pharmaceuticals, Inc.

$76.76

+2.41%

BMRN

BioMarin Pharmaceutical Inc.

$55.47

+1.08%

RXDX

Prometheus Biosciences, Inc.

$199.92

+0.09%

AXSM

Axsome Therapeutics, Inc.

$184.18

+3.28%